3NC
JAZZ icon

300 North Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

300 North Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$255K Sell
1,449
-23,235
-94% -$4.17M 1.56% 34
2015
Q1 		$4.26M Buy
24,684
+54
+0.2% +$9.27K 0.94% 46
2014
Q4 		$4.03M Buy
24,630
+4,524
+23% +$751K 0.93% 49
2014
Q3 		$3.23M Buy
+20,106
New +$3.09M 0.86% 50

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

300 North Capital's JAZZ Position: Q2 2015 in Review

300 North Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 94% in Q2 2015, selling an estimated $4.17M and leaving 1,449 shares worth $255K. The position accounts for 1.56% of the portfolio, ranked #34.

300 North Capital first reported a position in JAZZ in Q3 2014 and has held it in 4 quarters since. The position peaked at $4.26M in Q1 2015. 374 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

  • 300 North Capital held 1,449 shares of Jazz Pharmaceuticals worth $255K as of Q2 2015.
  • 300 North Capital sold 23,235 Jazz Pharmaceuticals shares in Q2 2015, an estimated $4.17M.
  • Jazz Pharmaceuticals made up 1.56% of 300 North Capital's portfolio in Q2 2015, its #34 holding.
  • 300 North Capital first reported a position in Jazz Pharmaceuticals in Q3 2014 and has held it in 4 quarters since.
  • 300 North Capital's Jazz Pharmaceuticals position peaked at $4.26M in Q1 2015.
  • 374 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.